Published in Clin Infect Dis on August 01, 2008
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
Immunological mechanisms of vaccination. Nat Immunol (2011) 3.35
Multiple layers of B cell memory with different effector functions. Nat Immunol (2009) 3.33
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology (2010) 2.61
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol (2012) 2.48
Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis (2014) 2.46
Systems vaccinology. Immunity (2010) 2.36
Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J Immunol (2012) 2.34
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One (2010) 2.24
Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis (2012) 2.18
Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med (2012) 2.17
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med (2011) 2.09
Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog (2009) 2.07
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog (2010) 2.03
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun (2013) 1.95
Few and far between: how HIV may be evading antibody avidity. PLoS Pathog (2010) 1.94
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat Rev Immunol (2012) 1.80
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J (2009) 1.72
A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun (2009) 1.68
Vaccines: the fourth century. Clin Vaccine Immunol (2009) 1.61
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med (2013) 1.59
Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther (2008) 1.59
New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis (2008) 1.58
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine (2009) 1.56
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 1.55
Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology (2011) 1.53
Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells. Nature (2008) 1.52
Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses (2011) 1.52
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol (2009) 1.50
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol (2012) 1.49
Immunity induced by a broad class of inorganic crystalline materials is directly controlled by their chemistry. J Exp Med (2014) 1.49
Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol (2014) 1.48
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One (2013) 1.47
Memory CD8+ T cell differentiation. Ann N Y Acad Sci (2010) 1.47
Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS One (2011) 1.43
Memory CD4 T cells that express CXCR5 provide accelerated help to B cells. J Immunol (2011) 1.43
Institutional shared resources and translational cancer research. J Transl Med (2009) 1.41
Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl. Int J Biostat (2011) 1.40
Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J Virol (2011) 1.38
Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS (2009) 1.36
Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest (2011) 1.33
Development of a vaccine against Staphylococcus aureus. Semin Immunopathol (2011) 1.32
Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci (2011) 1.28
A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A (2012) 1.23
Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Crit Rev Immunol (2010) 1.22
Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol (2010) 1.22
Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med (2011) 1.19
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest (2014) 1.18
Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.18
Safety and efficacy of neonatal vaccination. Eur J Immunol (2009) 1.17
mTOR, linking metabolism and immunity. Semin Immunol (2013) 1.17
Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology (2009) 1.16
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine (2009) 1.15
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol (2011) 1.13
Experimental rabies vaccines for humans. Expert Rev Vaccines (2010) 1.12
New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med (2014) 1.11
The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol (2010) 1.10
Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) (2010) 1.10
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine (2011) 1.07
Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees. Cytokine (2010) 1.06
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Stat Commun Infect Dis (2011) 1.06
Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med (2012) 1.05
Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J Control Release (2011) 1.05
Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proc Natl Acad Sci U S A (2015) 1.05
Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol (2009) 1.05
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect (2013) 1.04
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. Vaccines (Basel) (2014) 1.04
Killing of targets by CD8 T cells in the mouse spleen follows the law of mass action. PLoS One (2011) 1.04
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. PLoS One (2013) 1.04
Advances in structure-based vaccine design. Curr Opin Virol (2013) 1.04
An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses (2012) 1.03
Correlation analysis of intracellular and secreted cytokines via the generalized integrated mean fluorescence intensity. Cytometry A (2010) 1.02
Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 1.02
Young lives lost as B cells falter: what we are learning about antibody responses in malaria. J Immunol (2013) 1.02
Systems vaccinology: its promise and challenge for HIV vaccine development. Curr Opin HIV AIDS (2012) 1.01
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel) (2014) 1.01
Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS (2013) 1.01
Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys. J Virol (2010) 1.01
A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine (2013) 1.00
Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection. Proc Natl Acad Sci U S A (2015) 1.00
Structure-based vaccine design in HIV: blind men and the elephant? Curr Pharm Des (2010) 0.99
B cell TLRs and induction of immunoglobulin class-switch DNA recombination. Front Biosci (Landmark Ed) (2012) 0.99
Antigen dose and humoral immune response correspond with protection for inactivated infectious pancreatic necrosis virus vaccines in Atlantic salmon (Salmo salar L). Vet Res (2013) 0.98
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol (2015) 0.98
Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat Protoc (2013) 0.97
Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J Infect Dis (2010) 0.96
Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol (2013) 0.96